← Every sector
Health Care Stocks
Drug makers, biotechnology, medical devices, laboratory instruments, health insurers and hospitals. 185 companies worth $6.7T together, at a median P/E of 25.7.
Biological Products, (No Diagnostic Substances)
Largest first.
| Company | Market value | P/E |
|---|---|---|
| Amgen IncAMGNBiological Products, (No Diagnostic Substances) | $224.3B$414.87 | 25.7× |
| Gilead Sciences, IncGILDBiological Products, (No Diagnostic Substances) | $187.6B$151.17 | — |
| Moderna IncMRNABiological Products, (No Diagnostic Substances) | $89.8B$225.00 | — |
| Biogen IncBIIBBiological Products, (No Diagnostic Substances) | $33.3B$225.71 | 24.3× |
| Exelixis IncEXELBiological Products, (No Diagnostic Substances) | $14.9B$59.86 | 17.3× |
| Neurocrine Biosciences IncNBIXBiological Products, (No Diagnostic Substances) | $14.5B$142.44 | 20.5× |
| Halozyme Therapeutics IncHALOBiological Products, (No Diagnostic Substances) | $12.6B$110.42 | 30.4× |
| Bio-Techne CorpTECHBiological Products, (No Diagnostic Substances) | $11.3B$72.46 | 62.2× |
| Immunitybio IncIBRXBiological Products, (No Diagnostic Substances) | $11.1B$10.51 | — |
| Vaxcyte IncPCVXBiological Products, (No Diagnostic Substances) | $10.3B$71.38 | — |
| Twist Bioscience CorpTWSTBiological Products, (No Diagnostic Substances) | $10B$159.78 | — |
| Krystal Biotech IncKRYSBiological Products, (No Diagnostic Substances) | $9.8B$331.61 | 40.6× |
| Repligen CorpRGENBiological Products, (No Diagnostic Substances) | $9.8B$173.88 | 236.2× |
| Kodiak Sciences IncKODBiological Products, (No Diagnostic Substances) | $6.3B$99.87 | — |
| CRISPR Therapeutics AGCRSPBiological Products, (No Diagnostic Substances) | $5.2B$53.39 | — |
| Relay Therapeutics IncRLAYBiological Products, (No Diagnostic Substances) | $3.9B$17.88 | — |
| BioCryst Pharmaceuticals IncBCRXBiological Products, (No Diagnostic Substances) | $2.2B$8.55 | — |
| Novavax IncNVAXBiological Products, (No Diagnostic Substances) | $2.1B$12.75 | — |
| Ocugen IncOCGNBiological Products, (No Diagnostic Substances) | $324M$0.96 | — |
| Editas Medicine IncEDITBiological Products, (No Diagnostic Substances) | $283.8M$2.90 | — |
| Fate Therapeutics IncFATEBiological Products, (No Diagnostic Substances) | $254.4M$2.18 | — |
| Coherus Oncology IncCHRSBiological Products, (No Diagnostic Substances) | $165.3M$1.07 | 1.0× |
| Anavex Life Sciences CorpAVXLBiological Products, (No Diagnostic Substances) | $138.1M$1.49 | — |
| Humacyte IncHUMABiological Products, (No Diagnostic Substances) | $112.5M$0.41 | — |
Industries are the SEC's own codes for each company. Market value is the latest close times the shares on the latest filing; P/E is left out where earnings are not positive.